论文部分内容阅读
目的探讨肺源性心脏病急性加重期血清淀粉酶检测的临床意义。方法 45例肺心病急性加重期患者与40名健康体检者进行血清淀粉酶检测后,对比分析。结果肺心病急性加重期患者与健康人群血清淀粉酶结果差异有统计学意义(P<0.01),21例肺心病伴呼吸衰竭患者与24例无呼吸衰竭患者血清淀粉酶结果差异有统计学意义(P<0.05),20例肺心病患者治疗前后血清淀粉酶差异有统计学意义(P<0.05)。结论血清淀粉酶测定能客观反映肺心病病情,可以成为判定慢性肺心病病情轻重的一项指标。
Objective To investigate the clinical significance of serum amylase in acute exacerbation of pulmonary heart disease. Methods Forty-five patients with acute exacerbation of pulmonary heart disease and 40 healthy subjects were tested for serum amylase, then analyzed comparatively. Results Serum amylase results were significantly different between patients and healthy people in acute exacerbation of pulmonary heart disease (P <0.01), and there was significant difference in serum amylase between 21 patients with pulmonary heart disease and respiratory failure and 24 patients without respiratory failure (P < P <0.05). The serum amylase levels in 20 patients with pulmonary heart disease before and after treatment were significantly different (P <0.05). Conclusion Serum amylase assay can objectively reflect the condition of pulmonary heart disease and can be used as an indicator of the severity of chronic pulmonary heart disease.